Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHAIROS - Effect of early brief intensification by chemoimmunotherapy with FCR [fludaraine + cyclophosphamide + rituximab] followed by FR and Rituximab maintenance on clinical response in chemo-naive patients with B-CLL [B-cell chronic lymphocytic leukaemia].

Next Previous
X
Search
Trial Profile

CHAIROS - Effect of early brief intensification by chemoimmunotherapy with FCR [fludaraine + cyclophosphamide + rituximab] followed by FR and Rituximab maintenance on clinical response in chemo-naive patients with B-CLL [B-cell chronic lymphocytic leukaemia].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CHAIROS
  • Sponsors Roche

    • Most Recent Events

    • 20 Dec 2013 New source identified and integrated (ClinicalTrials.gov, NCT02013817)
    • 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2009 Planned number of patients changed from 57 to 40 as reported by Roche record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top